Sunridge Medical · Scottsdale, Arizona

Alternative Uterine Cancer Treatment

If you have uterine or endometrial cancer, call us. We can help you understand the next decision.

We review histology, stage, molecular classification, prior care and quality-of-life needs to identify a more individualized path forward.

Call Free: 1-800-923-7878 Tell Us About Your Diagnosis

New diagnoses, recurrence, advanced disease and second-opinion questions are welcome.

Talk With Our Uterine Cancer Patient Care Team

There is no charge to speak with our Patient Care Team about your uterine cancer diagnosis, ask practical questions and learn whether a physician consultation may be an appropriate next step.

Prefer to speak now?Call 1-800-923-7878This introductory call is free. It is not a medical consultation and does not establish a physician-patient relationship.

Integrative Oncology · Endometrial Cancer · Uterine Sarcoma

Alternative Uterine Cancer Treatment: Precision Oncology and Integrative Support

Most uterine cancers begin in the endometrium, and many early-stage cases can be cured with surgery. For higher-risk, advanced or recurrent disease, the treatment plan increasingly depends on histology and molecular biology—not a generic uterine-cancer label.

Sunridge Medical provides physician-directed integrative support around gynecologic oncology care, helping patients address symptoms, nutrition, movement, treatment tolerance, hormonal and sexual health, recovery and long-term quality of life.

Request a Uterine Cancer Consultation →Call 1-800-923-7878

Uterine cancer evaluation with pelvic anatomy, pathology, imaging and molecular testing

Early warningBleeding deserves evaluationPostmenopausal or unusual bleeding should be assessed promptly.

DiagnosisHistology comes firstEndometrial carcinoma and uterine sarcoma require different plans.

Precision careMolecular subtype mattersMMR, POLE and p53 classification can change risk and treatment.

Whole personSupport quality of lifeSymptoms, strength, nutrition and survivorship belong in the plan.

Understand the Diagnosis

Endometrial Carcinoma and Uterine Sarcoma Are Not the Same Disease

Endometrial carcinoma begins in the lining of the uterus and accounts for most uterine cancers. Uterine sarcomas arise from muscle or connective tissue and are uncommon. Their pathology, staging, expected behavior and treatment can differ substantially, so expert pathology review is especially valuable when the diagnosis is rare or uncertain.

Common histology

Endometrioid Carcinoma

This is the most common subtype. Grade, depth of myometrial invasion, lymphovascular invasion, stage and molecular class all influence risk.

Higher-risk carcinoma

Serous, Clear Cell and Carcinosarcoma

These cancers can behave more aggressively. Selected uterine serous cancers should be assessed for HER2 because it may create a targeted-treatment option.

Rare disease

Uterine Sarcoma

Leiomyosarcoma, endometrial stromal sarcoma and other sarcomas need their own expert treatment pathway rather than an endometrial-cancer template.

Inherited risk

Think About Lynch Syndrome

Mismatch-repair testing helps guide immunotherapy and can identify patients who should discuss germline testing for Lynch syndrome.

Modern Classification Changes the Conversation

Ask What the Pathology and Molecular Results Mean for Your Plan

The National Cancer Institute now encourages complete molecular classification of endometrial cancers when feasible. The four major groups—POLE-mutated, mismatch-repair deficient, no specific molecular profile and p53-abnormal—carry different prognostic information and can influence adjuvant and systemic treatment decisions.

Pathology: confirm histologic type, grade, myometrial invasion, cervical or adnexal involvement, lymphovascular invasion, margins and lymph-node findings.
MMR or MSI: informs Lynch-syndrome assessment and predicts strong sensitivity to checkpoint immunotherapy in many advanced cancers.
POLE and p53: help define favorable and higher-risk molecular groups when interpreted with stage and histology.
ER and PR: may support hormonal therapy in selected low-grade, slower-growing or recurrent cancers.
HER2: is relevant for selected serous or p53-abnormal tumors and may open a trastuzumab-based option.
Imaging: ultrasound, MRI, CT or PET may be used according to symptoms, pathology and stage.

Do not wait on natural therapies when bleeding is unexplained. Postmenopausal bleeding, bleeding between periods or persistent abnormal discharge needs timely medical evaluation. Integrative care should not delay biopsy, staging or potentially curative surgery.

Treatment by Stage, Histology and Molecular Risk

Build the Conventional Backbone First—Then Add Coordinated Support

Surgery is central for most operable endometrial cancers and many uterine sarcomas. The usual endometrial-cancer operation includes hysterectomy with removal of both ovaries and fallopian tubes, plus lymph-node assessment when appropriate. Radiation, chemotherapy, hormonal therapy, immunotherapy, targeted therapy and clinical trials are selected according to the individual disease.

Early-stage disease

Surgery May Be Curative

Some patients need surgery alone. Others benefit from vaginal brachytherapy, pelvic radiation, chemotherapy or combined treatment based on recurrence risk and molecular classification.

Advanced or recurrent carcinoma

Chemoimmunotherapy Has Changed Care

Carboplatin and paclitaxel combined with a checkpoint inhibitor is now an important first-line option. Benefit is especially pronounced in mismatch-repair-deficient cancers, although approvals extend more broadly.

Biology-selected therapy

Hormonal and HER2-Directed Options

Hormonal therapy can be appropriate for selected ER/PR-positive, lower-grade cancers. HER2-positive uterine serous cancers may benefit from trastuzumab added to chemotherapy.

Uterine sarcoma

Histology-Specific Expertise

Surgery is often central when disease is resectable. Radiation, hormone therapy and systemic drugs are chosen by sarcoma subtype, stage, receptor status, prior care and goals.

Advanced Does Not Mean There Is Only One Path

Modern treatment is more personalized than it was even a few years ago. A review of pathology, molecular results, prior therapy, sites of disease, symptoms and goals may identify immunotherapy, hormonal, targeted, surgical, radiation or clinical-trial options that were not part of an older plan.

Integrative Care Around Oncology Treatment

Use Natural and Supportive Therapies With Clear Goals

Sunridge’s integrative approach is designed to support the patient around gynecologic oncology care—not to substitute for biopsy, surgery, radiation, chemotherapy, immunotherapy or other treatments with curative or disease-control potential. A safe plan accounts for medications, kidney and liver function, blood counts, bleeding risk, treatment timing and current symptoms.

Nutrition

Protect Intake and Metabolic Health

Individualized nutrition can address appetite, nausea, bowel changes, weight loss or gain, diabetes risk and protein needs without promising that a restrictive diet can cure uterine cancer.

Movement

Rebuild Strength Gradually

Walking, mobility work and progressive resistance exercise can support function and recovery when adjusted for surgery, anemia, neuropathy, fatigue and baseline fitness.

Symptoms

Treat What Limits Daily Life

Pain, fatigue, sleep problems, hot flashes, lymphedema, bowel or bladder changes, neuropathy and sexual-health concerns deserve active assessment and management.

Mind-body care

Support Anxiety and Mood

Mindfulness, yoga, relaxation practices and psychological care may help selected patients with anxiety or depressive symptoms when tailored to ability and preference.

Supplements and IV therapies require coordination. Products described as natural can still affect bleeding, anesthesia, drug metabolism, hormone-sensitive disease or treatment toxicity. Sunridge’s IV vitamin C / ascorbic acid information describes an adjunctive, investigational approach—not a proven replacement for uterine cancer treatment.

Quality of Life, Menopause and Survivorship

Plan for Recovery, Hormonal Health and the Life You Want to Protect

Hysterectomy, removal of the ovaries, pelvic radiation and systemic therapies can affect menopause symptoms, bone health, sexuality, fertility, bladder or bowel function and emotional well-being. These issues are not secondary to cancer care; they are part of it.

Woman with uterine cancer and family member discussing treatment and quality of life with clinicians

Coordinate the Whole Plan

Discuss fertility preservation before treatment if future pregnancy matters and the cancer situation allows time.
Ask how surgery or treatment may affect ovarian function, menopause symptoms and bone health.
Report lymphedema, pelvic pain, urinary or bowel changes, bleeding and new neurologic symptoms.
Address vaginal dryness, pain with sex, body image and intimacy without embarrassment.
Use individualized movement, sleep, nutrition and emotional support during recovery and surveillance.

Exercise trials in endometrial-cancer survivors suggest that structured aerobic and resistance programs are feasible and may improve fitness, function and patient-reported outcomes. They should be personalized rather than described as cancer treatment.

Prepare for a Useful Consultation

What to Send Before a Uterine Cancer Review

Complete biopsy, dilation-and-curettage and surgical pathology reports.
Operative report, hospital discharge summary and lymph-node findings.
MMR or MSI, POLE, p53, ER/PR, HER2 and other molecular-testing reports when performed.
Pelvic ultrasound, MRI, CT or PET reports and access to the actual images when possible.
Radiation records and all chemotherapy, immunotherapy, hormonal or targeted-treatment details.
Current medication and supplement list, allergies and recent laboratory results.
Family history of colorectal, endometrial, ovarian and other Lynch-associated cancers.
Your priorities regarding symptom control, fertility, menopause, sexuality, work and quality of life.

Ask What Records to Send →Speak With Patient Care

Questions Patients Ask

Uterine Cancer Consultation FAQs

Is uterine cancer the same as endometrial cancer?

Not exactly. Endometrial cancer begins in the uterine lining and is the most common uterine cancer. Uterine sarcoma begins in muscle or connective tissue and follows a different treatment pathway.

Why do MMR, POLE and p53 results matter?

They help place endometrial cancers into molecular groups with different prognoses and treatment implications. Mismatch-repair deficiency can also identify patients likely to benefit from immunotherapy and those who should consider Lynch-syndrome evaluation.

Can advanced or recurrent uterine cancer still be treated?

Yes. Depending on histology, molecular results, prior care and sites of disease, options may include surgery, radiation, chemotherapy, immunotherapy, hormonal therapy, targeted treatment and clinical trials.

Can Sunridge work with my gynecologic oncologist?

Yes. Integrative care is safest when pathology, imaging, medications, supplements and supportive therapies are coordinated with the gynecologic oncology team.

Can I use natural therapies instead of surgery?

Natural and supportive therapies have not been proven to replace potentially curative surgery for operable uterine cancer. A patient considering delay or refusal should first understand the purpose, expected benefit and risks of the recommended treatment.

Can supplements interfere with treatment?

Yes. Supplements can affect bleeding, anesthesia, liver enzymes, drug metabolism, hormone-sensitive disease and laboratory results. Bring every product and dose for review before surgery or systemic treatment.

Primary Sources and Research

References

Medical information is educational and not a diagnosis or treatment recommendation. Uterine cancer requires care from a qualified gynecologic oncology team. Outcomes cannot be guaranteed.

Ready to Take the Next Step?

Build a Uterine Cancer Plan Around the Biology and the Person

Whether you are newly diagnosed, preparing for surgery, receiving adjuvant treatment, living with advanced disease, recovering after care or seeking another opinion, our Patient Care Team can help organize the records and next questions.

Request a Uterine Cancer Consultation →Call 1-800-923-7878

Scottsdale clinic · Serving Greater Phoenix

Integrative Uterine Cancer Care in Scottsdale, Arizona

Sunridge Medical provides physician-directed integrative support for people facing uterine cancer at our Scottsdale clinic. We serve patients from Scottsdale, Phoenix, the Greater Phoenix area and people traveling to Arizona for care.

Care can be individualized around histology, molecular classification, stage, surgery, systemic treatment, hormone considerations and recovery.

Visit Sunridge in Scottsdale

14200 N Northsight Blvd, Suite 160
Scottsdale, Arizona 85260
Map, parking and directions →

Speak with our Patient Care Team

Call 1-800-923-7878 for a free introductory conversation about your diagnosis and next steps.

Coming from Phoenix or farther away?

Our team can help you understand scheduling and plan a visit to the Scottsdale clinic.

Tell Us What You Are Facing Call 1-800-923-7878 Plan Your Visit

Cancer care that happens here

Start Here

Cancers We Treat

Treatment & Planning